# One-Page Clinician Packet — Case Summary
**Patient:** Chad T. Mansfield  •  **Date:** {{fill-in}}  
**Supervising Teams:** VA Endocrinology & MICU (72-h fast)  •  **Consult:** Dr. Kevin Niswender; Dr. Pruett

## Executive Summary
During a supervised 72-hour fast, glucose remained elevated (≈120–140 mg/dL) with suppressed ketogenesis (β-HB <0.2 mmol/L) until quetiapine was given near the end, after which ketosis began. Pattern suggests **hepatic-selective insulin resistance with sympathetic/HPA dominance** and **impaired mitochondrial substrate switching**. Historical response to **tirzepatide** normalized fasting glucose and improved function; metformin did not.

## Key Objective Data
- **Most recent (11/12/2025):** Glucose 131 mg/dL; Insulin 10.5 µIU/mL; C-peptide 2.0 ng/mL; β-HB <0.2 mmol/L  
- **Adrenal:** Cortisol (AM) 11 µg/dL; **DHEA-S 42 µg/dL (low)**  
- **Liver:** ALT 46 / AST 32 U/L (mild stress)  
- **Lipids:** LDL 106, HDL 48, TG 112 mg/dL  
- **Heme:** Platelets 143 K/µL (borderline low)  
- **Thyroid:** Euthyroid; rT3 mildly elevated (stress-adaptive)

## Figures & Tables (repo)
- Timeline (72-h fast with quetiapine→ketosis): `figures/timeline_fast_case.png`  
- Three-lane timeline: `figures/three_lane_timeline.png`  
- Latest labs CSV: `data/labs_2025-11-12.csv`  
- Trends (to be populated from Nightscout/Apple Health/Pillow): `data/plots/`

## Differential (ranked)
1) Hepatic-selective insulin resistance with HPA/sympathetic dominance  
2) Mitochondrial substrate-switching defect (functional/acquired > primary)  
3) Autonomic/MCAS interplay affecting catechol-/estrogen clearance  
4) Adrenal partial insufficiency vs rigidity (less likely)  
5) Insulinoma (unlikely)

## Proposed Confirmatory Workup
- **Counter-regulation:** glucagon, FFA, lactate/pyruvate, total/free carnitine + acylcarnitines  
- **Switching:** 6-h mini-fast β-HB trajectory; CGM overlays  
- **Endocrine context:** AM cortisol + DHEA-S trend; ACTH; IGF-1 (± IGFBP-3)  
- **Autonomic:** active stand test, HRV diary (5–6 AM symptom window)

## Therapeutic Considerations
- **Reinitiate tirzepatide** (2.5 mg → 5 mg; MD-directed): dual GLP-1/GIP improves hepatic insulin signaling, suppresses glucagon, aids metabolic flexibility.  
- **TRT hygiene:** micro-dose EOD; stable AI; maintain hCG; reassess DHEA-S after E2 stable.  
- **Non-pharm:** circadian anchors; graded Zone-2; protein-first refeeds; MCAS-aware diet.

## Learning Points
- Fasting hyperglycemia with suppressed ketogenesis can be **central/ANS-amplified hepatic IR**.  
- **Quetiapine-linked ketosis onset** is a useful physiologic probe of sympathetic gating.  
- Dual incretin therapy may restore **metabolic flexibility** where metformin/lifestyle fail.

**Contact:** Chad T. Mansfield (ISSA-CPT)  •  Repo: case_study
